We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

MINDRAY In-Vitro Diagnostics

  Gold Mindray offers a range of chemistry and hematology analyzers, designed to meet the needs of smaller labs as a main in... read more Featured Products: More products

Download Mobile App





Mindray Analyzers Help Detect Hematological Parameters to Support COVID-19 Diagnosis and Prognosis

By LabMedica International staff writers
Posted on 19 Apr 2021
Print article
Image: Mindray Analyzers Help Detect Hematological Parameters to Support COVID-19 Diagnosis and Prognosis (Photo courtesy of Mindray)
Image: Mindray Analyzers Help Detect Hematological Parameters to Support COVID-19 Diagnosis and Prognosis (Photo courtesy of Mindray)
Mindray (Shenzhen, China) hematology analyzers are using advanced technologies to detect inflammatory parameters, such as white blood cell count (WBC), neutrophil count, neutrophil-to-lymphocyte ratio (NLR) and red blood cells (RBC) that can support COVID-19 diagnosis and prognosis.

Identifying COVID-19 patients at highest risk for severe disease is important. In order to facilitate early intervention and to manage local hospital resources to mitigate the critical care crises, research is being conducted in routine, low-cost, and suggestive parameters to assist with COVID-19 prognosis and the identification of severe cases. Studies comparing hematological results from good and poor outcome groups of COVID-19 patients have revealed that the best single parameter for predicting the prognosis of severe patients is RDW-SD. Additionally, combined parameters Lym# & RDW-CV as well as Lym# & RDW-SD are better for predicting the prognosis of severe COVID-19. Researchers have also found that HGB is lower in the severe group than in the moderate group. New joint parameters Lym% and HGB have the best sensitivity and specificity. Hence, Lym% and HGB can be used as indicators of disease prognosis.

With advanced technologies, the newly combined hematological parameters, such as Lym% & RDW-SD, Lym# & HGB and NLR & RDW-SD, have been found as supportive predictors during COVID-19 prognostics. More and more covariates can be studied and developed on the Mindray BC-6000 series analyzers. Especially on BC-6800Plus, the RET channel can detect the number, size, and hemoglobin concentration of RBCs and RETs highly sensitive laser scattering technology. Thus, it is recommended to start using self-defined parameters for COVID-19 prognosis now.


New
Gold Supplier
TRANSPORT MEDIUM
TRANSPORT MEDIUM-2
New
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software
New
COVID-19 Test
CLART COVID-19
New
Disposable Virus Sampling Tube
Disposable Virus Sampling Tube

Print article
BIOHIT  Healthcare OY

Channels

Clinical Chem.

view channel
Image: Blood test for  plasma aldosterone concentration was used to screen For hyperaldosteronism in hypertensive men (Photo courtesy of  VisitHealth Ltd)

Urinary Sodium/Potassium Ratio Screens for Hyperaldosteronism in Hypertensive Men

Among individuals with hypertension, the prevalence of secondary hypertension has been reported to be around 10%. More than half of individuals with secondary hypertension have associated hyperaldosteronism.... Read more

Industry

view channel
Illustration

Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028

The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.